Bioanalytical methods, strategies and outlook for antibody-drug conjugate trials

Antibody-drug conjugates (ADCs) are formed by antibodies targeting a specific antigen or antibody fragment covalently attached to payloads (such as small molecule cytotoxic drugs) via a linker. The primary goal of ADCs is to target the payload to specific sites through the antibody, combining the potent cytotoxic effects of traditional small molecule drugs with the tumor-targeting characteristics of antibody drugs.